Objective To investigate the effects of oral administration of low-dose propranolol on heart rate variability (HRV), acceleration capacity (AC), deceleration capacity (DC), and cardiac conduction in the treatment of infantile hemangioma. Methods A total of 118 infants with hemangioma (≤1 year) were enrolled, and 24-hour ambulatory electrocardiography was performed before oral administration of low-dose propranolol and after one month of administration. The changes in time-domain indices [standard deviation of all normal sinus RR intervals (SDNN), standard deviation of all mean 5-minute RR intervals (SDANN), root mean squared successive difference (RMSSD), and percentage of successive normal sinus RR intervals >50 ms (PNN50)] and frequency-domain indices [low frequency (LF) and high frequency (HF)] for HRV, AC, and DC were observed, as well as abnormalities in cardiac conduction and other aspects after administration of propranolol. Results After administration of propranolol, the infants had significantly increased SDNN, RMSSD, LF, HF, and PNN50 (P<0.01), and significantly reduced AC, mean heart rate (HR) and minimum HR (P<0.01). The 24-hour ambulatory electrocardiographic findings showed a nonsignificantly higher abnormal rate after administration of propranolol. Conclusions In the treatment of infantile hemangioma, propranolol can inhibit the activity of sympathetic nerve and block cardiac conduction, but without any serious adverse effect.
Key words
Hemangioma /
Propranolol /
Heart rate variability /
Heart rate acceleration capacity /
Heart rate deceleration capacity /
Infant
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
[1] 郭继鸿. 心率减速力检测[J]. 临床心电学杂志, 2009, 18(1): 59-68.
[2] Shah S, Frieden IJ. Treatment of infantile hemangiomas with beta-blockers: a review[J]. Skin Therapy Lett, 2013, 18(6): 5-7.
[3] Marqueling AL, Oza V, Frieden IJ, et al. Propranolol and infantile hemangiomas four years later: a systematic review[J]. Pediatr Dermatol, 2013, 30(2): 182-191.
[4] 王亚飞, 周权, 王忠强. 小剂量盐酸普萘洛尔口服治疗不同月龄婴幼儿血管瘤临床疗效观察[J]. 中国口腔颌面外科杂志, 2015, 13(1): 38-41.
[5] Holmes WJ, Mishra A, Gorst C, et al. Propranolol as first-line treatment for infantile hemangiomas[J]. Plast Recontr Surg, 2010, 125(1): 420-421.
[6] Gunturi N, Ramqopal S, Balaqopal S, et al. Propranolol therapy for infantile hemangioma[J]. Indian Pediatr, 2013, 50(3): 307-313.
[7] 郑家伟, 周琴, 王延安, 等. 口腔颌面部血管瘤治疗指南[J]. 中国口腔颌面外科杂志, 2011, 9(1): 61-67.
[8] Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, et al. Propranolol for severe hemangiomas of infancy[J]. N Engl J Med, 2008, 358(24): 2649-2651.
[9] 郑家伟, 张凌, 陈正岗. 普萘洛尔治疗婴幼儿血管瘤专家共识[J]. 中国口腔颌面外科杂志, 2013, 11(2): 161-164.
[10] 王明森, 王洪光. 盐酸普萘洛尔缓释片的研究[J]. 西北药学杂志, 2009, 24(6): 469-471.
[11] Zhou HH, Koshakji RP, Silberstein DJ, et al. Altered sensitivity to and clearance of propranolol in men of Chinese descent as compared with American whites[J]. N Engl J Med, 1989, 320(9): 565-570.
[12] 付时章, 黄和平, 黄琳玲. 口服普萘洛尔治疗婴幼儿体表血管瘤临床观察[J]. 中国美容医学, 2014, 23(17): 1449-1453.
[13] 孙中运, 衣明纪. 普萘洛尔治疗婴儿血管瘤的临床疗效及风险[J]. 中国药师, 2011, 14(1): 124-126.
[14] 易兰芬, 文红霞, 邱梅. 健康婴儿心率减速力和心率变异性的变化及其相关性[J]. 临床儿科杂志, 2014, 32(1): 30-32.
PDF(1617 KB)
